FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FY 2018 OGD Research Grants

The Office of Generic Drugs science and research report for FY 2018 says 13 research contracts and 11 grants for innovative research were funded.

Federal Register

Info Collection Extension for CDRH Appeals Process

Federal Register notice: FDA submits to OMB an information collection extension for Center for Devices and Radiological Health Appeals Processes.

Human Drugs

Novartis Reserves $700 Million to Settle Whistleblower Suit

Novartis says it has reserved about $700 million to settle U.S. government allegations that it illegally enticed physicians to prescribe its drugs.

Human Drugs

Horizon NDA Accepted for New Procysbi Dosage Form

FDA accepts for review a Horizon Therapeutics NDA for a new dosage form for Procysbi (cysteamine bitartrate) delayed-release oral granules in packets...

FDA General

Consent Decree Entered Against J and L Grocery

An Arkansas federal court orders J and L Grocery (Alma, AR) to stop distributing drug products, medical devices, cosmetics and food until the company ...

Human Drugs

62% of FDA-approved Biologics Have Boxed Warnings

A Milwaukee Journal Sentinel investigative report says 62% of biologics approved by FDA carry a Boxed Warning, much higher than the percentage for new...

Federal Register

Info Collection Extension for Emergency Use Guide

Federal Register notice: FDA seeks an information collection extension on its guidance on emergency use authorizations.

Human Drugs

Amarin Planning Synthetic Omega-3 Response

Amarin says it will respond to a citizen petition asking for a synthetic omega-3 exclusion from dietary supplement structural requirements by demonstr...

Federal Register

Draft Guide on Prostate Cancer Drugs

Federal Register notice: FDA makes available a draft guidance entitled Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues....

Human Drugs

Review iPLEDGE Isotretinoin Fetal Defects: Researchers

Researchers call for reevaluation of the iPLEDGE isotretinoin program and exploration of new approaches to lower fetal exposure to the drug.